Douglas Love
CEO, President & Director
Yes. Hi, Pete, and thanks, Cantor, for welcoming Annexon to this year’s conference. Happy to be here. I think this is our fifth or sixth in a row. So we’re excited by that.
So I’m Doug Love, as Pete said President and CEO of Annexon, Founding CEO of the company. We started the company roughly 10 years ago, focused on the classical complement pathway. And importantly, what’s unique about our approach is we’re targeting the most upstream aspect of classical complement which localizes on disease tissue and drives a damaging inflammatory disease process in a host of diseases across the body, brain and eye.
What’s unique about what we are doing is all of our programs are first in kind or pioneering, and we’re really pleased with the consistency in the outcomes we’ve seen across all of our programs. We’re led by 3 flagship programs. Guillain-Barré syndrome is our most advanced program, having completed a robust Phase III program, and we’re now in dialogue with regulators across the globe for approval worldwide.
Tanruprubart in geographic atrophy — or vonaprument, I’m sorry, in geographic atrophy is our second flagship program. It’s the world’s largest GA Phase III program, the only program to have demonstrated significant preservation against
Read the full article here